IRIS Institutional Research Information System - OPENBS Open Archive UniBS

BERRUTI, ALFREDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 40.652
AS - Asia 16.497
EU - Europa 12.218
SA - Sud America 3.676
Continente sconosciuto - Info sul continente non disponibili 1.067
AF - Africa 355
OC - Oceania 37
Totale 74.502
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 39.673
SG - Singapore 5.779
CN - Cina 5.071
BR - Brasile 2.997
UA - Ucraina 2.782
IT - Italia 2.054
HK - Hong Kong 1.917
DE - Germania 1.622
VN - Vietnam 1.215
PL - Polonia 985
GB - Regno Unito 821
FI - Finlandia 820
FR - Francia 797
RU - Federazione Russa 718
TR - Turchia 616
BD - Bangladesh 575
IE - Irlanda 526
CA - Canada 489
IN - India 361
AR - Argentina 242
EE - Estonia 216
MX - Messico 168
ID - Indonesia 157
SE - Svezia 152
NL - Olanda 147
IQ - Iraq 135
JP - Giappone 128
ZA - Sudafrica 121
CZ - Repubblica Ceca 113
EC - Ecuador 112
ES - Italia 106
CO - Colombia 82
VE - Venezuela 70
AT - Austria 66
SA - Arabia Saudita 65
PK - Pakistan 63
BE - Belgio 61
CR - Costa Rica 57
JM - Giamaica 52
MA - Marocco 51
PY - Paraguay 50
UZ - Uzbekistan 50
CL - Cile 48
LT - Lituania 47
HN - Honduras 44
AE - Emirati Arabi Uniti 39
IL - Israele 39
EG - Egitto 32
AU - Australia 30
CH - Svizzera 30
NG - Nigeria 29
PE - Perù 29
KE - Kenya 28
DZ - Algeria 27
KZ - Kazakistan 26
PH - Filippine 26
JO - Giordania 24
TT - Trinidad e Tobago 24
UY - Uruguay 24
GT - Guatemala 22
SV - El Salvador 22
AZ - Azerbaigian 21
LB - Libano 21
TN - Tunisia 21
AL - Albania 20
NP - Nepal 20
DK - Danimarca 19
KR - Corea 19
TH - Thailandia 19
PT - Portogallo 17
EU - Europa 16
NI - Nicaragua 16
BO - Bolivia 15
PR - Porto Rico 15
BG - Bulgaria 14
PA - Panama 14
MY - Malesia 13
RO - Romania 13
BB - Barbados 11
CW - ???statistics.table.value.countryCode.CW??? 11
TW - Taiwan 11
ET - Etiopia 10
HU - Ungheria 10
IR - Iran 10
PS - Palestinian Territory 10
KG - Kirghizistan 9
LV - Lettonia 9
OM - Oman 9
BH - Bahrain 8
DO - Repubblica Dominicana 8
GR - Grecia 8
SC - Seychelles 8
MK - Macedonia 7
CY - Cipro 6
GP - Guadalupe 6
MD - Moldavia 6
NZ - Nuova Zelanda 6
BS - Bahamas 5
GY - Guiana 5
KW - Kuwait 5
Totale 73.343
Salva come PNG Salva come JPEG
Città #
Fairfield 4.235
Ashburn 3.551
Woodbridge 3.241
Singapore 2.983
Houston 2.255
Hong Kong 1.905
Jacksonville 1.888
San Jose 1.792
Seattle 1.753
Cambridge 1.595
Wilmington 1.381
Ann Arbor 1.362
Beijing 1.283
Council Bluffs 1.126
The Dalles 1.083
Warsaw 959
Princeton 887
New York 863
Chandler 728
Los Angeles 726
Dallas 659
Helsinki 579
Chicago 566
Lauterbourg 493
Dublin 478
Istanbul 473
Nanjing 473
Ho Chi Minh City 418
Munich 301
Santa Clara 295
Buffalo 283
Brescia 277
São Paulo 248
Des Moines 235
Milan 231
Redondo Beach 226
Columbus 220
Hanoi 220
Dearborn 201
Moscow 198
Salt Lake City 198
San Diego 196
North Bergen 193
Tallinn 191
Nanchang 188
Shanghai 182
San Francisco 180
Boardman 165
Changsha 155
London 145
Shenyang 141
Orem 134
Hebei 133
Phoenix 120
Turku 116
Brooklyn 115
Rome 113
Atlanta 109
Toronto 109
Tianjin 105
Tampa 96
Montreal 95
Jinan 94
Rio de Janeiro 92
Jakarta 88
Nuremberg 87
Tokyo 87
Elk Grove Village 86
Brno 80
Dong Ket 80
Denver 77
Secaucus 76
Stockholm 71
Brasília 70
Jiaxing 70
Hangzhou 69
Belo Horizonte 67
Dalmine 66
Boston 63
Frankfurt am Main 63
Charlotte 61
Johannesburg 60
Mexico City 60
Naples 59
Washington 58
Chennai 57
Lappeenranta 57
Romola 57
Verona 57
Lancaster 56
Orange 56
Kunming 54
Poplar 54
Da Nang 53
Guangzhou 53
Brussels 52
Kocaeli 51
Zhengzhou 51
Haiphong 48
Newark 48
Totale 48.337
Salva come PNG Salva come JPEG
Nome #
Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer 804
Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. 389
Adrenocortical carcinoma xenograft in zebrafish embryos as model to study the in vivo cytotoxicity of abiraterone acetate 335
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors 315
GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity 303
Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma 299
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up† 285
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 273
Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures 271
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study 268
Eight‐week interval in flushing and locking port‐a‐cath in cancer patients: A single‐institution experience and systematic review 267
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. 263
In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures☆ 262
Excess of second tumors in denosumab-treated patients: A metabolic hypothesis 261
Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review 260
IN VITRO ANTITUMOR ACTIVITY OF PROGESTERONE IN HUMAN ADRENOCORTICAL CARCINOMA 251
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer 245
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case 243
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer 240
Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells 236
Clinical and histological prognostic factors of recurrent and/or metastatic salivary gland adenoid cystic carcinoma 234
Immunotherapy failure in adrenocortical cancer: where next? 231
Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy 231
Pros-IT CNR: an Italian prostate cancer monitoring project 230
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials 224
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement 223
Neoadjuvant treatment approach: The rosetta stone for breast cancer? 221
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents 221
Management of Severe Cushing Syndrome Induced by Adrenocortical Carcinoma with Abiraterone Acetate: A Case Report 220
Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma 219
Genetic Polymorphisms as Possible Factors Involved in the Onset of Anthracycline-Induced Cardiomyopathy 218
Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy 218
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines 212
Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy 211
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. 211
Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report 209
The guanine nucleotide exchange factor VAV2 as a new prognostic parameter in adrenocortical carcinoma 209
Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria 209
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509) 207
Should Adjuvant Weekly Paclitaxel Be Considered Less Efficacious Than Anthracyclines Plus Cyclophosphamide for Lower Risk Patients With Early-Stage Breast Cancer? 203
Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis 203
Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity 203
Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study 202
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 201
Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies. 201
Progression of vertebral fractures in metastatic melanoma and non-small cell lung cancer patients given immune checkpoint inhibitors 199
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 198
Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature 195
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options 195
Palbociclib inhibits proliferation of human adrenocortical tumor cells 194
Regression of advanced neuroendocrine tumors among patients receiving placebo 194
The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients 194
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† 194
Antineoplastic Activity of Artemisinin in Adrenocortical Carcinoma 194
Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice 193
Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells 192
A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report 192
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. 188
828PBONE METASTASES FROM RCC ARE NOT ALWAYS ASSOCIATED WITH A POOR PROGNOSIS 187
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 187
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement 186
Biological bases of radical prostatectomy in the management of prostate cancer patients with oligometastatic disease 185
A current perspective on treatment of adrenocortical carcinoma 184
A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma 183
Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. 182
Adjuvant bisphosphonates in patients with breast cancer: Does the potency matter? 182
Effect of primary letrozole treatment on tumor expression of mTOR and HIF-1α and relation to clinical response 182
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 182
Changes in body composition in early breast cancer patients treated with aromatase inhibitors 181
Osimertinib in EGFR Mutation–Positive Advanced NSCLC 181
Cisplatin Cytotoxicity in Human Testicular Germ Cell Tumor Cell Lines Is Enhanced by the CDK4/6 Inhibitor Palbociclib 180
Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines? 180
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature 179
CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs) 179
Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer? 178
Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method 178
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 178
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports 177
Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients 177
Leptomeningeal metastasis from solid tumors: a diagnostic and therapeutic challenge. 176
Clinical presentation and outcome of patients with enteric-type adenocarcinoma of the lung: A pooled analysis of published cases 175
Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis 175
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients 175
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study 174
Gonadal function in male patients with metastatic renal cell cancer treated with sunitinib: Effects of testosterone replacement on quality of life. 174
Serum vitamin D and prostate cancer prognosis: The story continues 174
When should everolimus be administered in the natural history of pancreatic neuroendocrine tumors? 174
Exemestane with ovarian suppression in premenopausal breast cancer. 174
Baseline prognostic factors affecting survival in recurrent and/or metastatic salivary gland adenoid cystic carcinoma 174
Belzutifan for Advanced Pheochromocytoma or Paraganglioma 173
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. 173
Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report 171
5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma 171
Fat Fraction Extracted from Whole-Body Magnetic Resonance (WB-MR) in Bone Metastatic Prostate Cancer: Intra- and Inter-Reader Agreement of Single-Slice and Volumetric Measurements 170
Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma 169
Abiraterone and increased survival in metastatic prostate cancer 169
MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects 168
Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance 168
Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma 167
Aspergillosis superinfection as a cause of death of crizotinib-induced interstitial lung disease successfully treated with high-dose corticosteroid therapy 165
Totale 21.380
Salva come PNG Salva come JPEG
Categoria #
all - tutte 361.423
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 361.423
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.434 0 0 0 213 50 182 214 234 194 349 267 731
2022/20232.586 497 83 74 178 191 712 10 212 347 44 115 123
2023/20243.948 180 96 316 217 207 696 109 145 1.039 118 48 777
2024/202510.895 98 74 98 1.510 1.168 737 591 293 1.088 803 2.697 1.738
2025/202620.305 1.636 2.770 1.934 3.138 1.553 1.223 2.697 784 1.253 1.786 954 577
2026/20276.801 852 1.033 1.638 3.278 0 0 0 0 0 0 0 0
Totale 74.502